Compare EWTX & KFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | KFY |
|---|---|---|
| Founded | 2017 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 2021 | 1998 |
| Metric | EWTX | KFY |
|---|---|---|
| Price | $30.05 | $62.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $34.71 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 691.3K | 491.2K |
| Earning Date | 05-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | ★ 3.20% |
| EPS Growth | N/A | ★ 42.41 |
| EPS | N/A | ★ 2.61 |
| Revenue | N/A | ★ $1,819,519,000.00 |
| Revenue This Year | N/A | $5.60 |
| Revenue Next Year | N/A | $4.16 |
| P/E Ratio | ★ N/A | $22.98 |
| Revenue Growth | N/A | ★ 12.20 |
| 52 Week Low | $10.60 | $58.95 |
| 52 Week High | $31.82 | $78.50 |
| Indicator | EWTX | KFY |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 46.37 |
| Support Level | $13.56 | $62.46 |
| Resistance Level | $30.77 | $70.29 |
| Average True Range (ATR) | 1.49 | 2.19 |
| MACD | -0.16 | -0.25 |
| Stochastic Oscillator | 52.72 | 37.77 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.